There has been a significant amount of M&A in the contract drug manufacturing sector, and established players are investing to get their piece of the growth as well. Canada's Patheon is now reaping the rewards of its own decision to expand.
Boehringer Ingelheim sees a wealth of opportunity in China's burgeoning pharma scene, and the German drug giant is plotting to open a contract manufacturing facility in Shanghai to cash in on biologics demand.
Lots of international drugmakers are opening plants in China to manufacture their products for a growing middle class looking for Western medicines. But Germany's Boehringer Ingelheim is taking a different tact. It will build a biologics plant there and offer contract manufacturing to the growing number of Chinese companies developing their own drugs.
The endorsement comes as San Francisco-based Rock Health announces a new class of 11 startups for its accelerator program, which provides access to guidance, financing and experts to help the young operations succeed.
Boehringer Ingelheim took another step forward in its quest to build an oncology division, reporting positive--though slim--progression-free and overall survival data for nintedanib in a population of patients with advanced non-small cell lung cancer.
As part of a broad partnership to advance diabetes treatments, Boehringer Ingelheim and Eli Lilly have unveiled an educational effort with an online video game called Complications Combat.
Just months after signing a consent decree for the manufacturing mess in its Ben Venue subsidiary, Boehringer Ingelheim finds itself on the firing line with the FDA again, this time for particle contamination in an API produced 4 and 5 years ago.
Boehringer Ingelheim, whose contract manufacturing facility in Bedford, Ohio, has been at the heart of huge drug disruptions in the U.S., is now feeling the sting of FDA inspectors at a key plant in Europe.
A safety watchdog group has analyzed the FDA's adverse event data on the entire GLP-1 class of diabetes drugs, finding more reports of pancreatitis and pancreatic cancer for these drugs compared with older treatments.
Boehringer Ingelheim Venture Fund, the VC unit of the Germany-based pharma group, has injected an undisclosed amount of capital into Eyevensys, which uses electro-transfer in a gene therapy approach to treat ocular diseases.